Literature DB >> 33431472

Complete heart block as a herald sign for cardiac lymphoma.

Holly P Morgan1, Muram El-Nayir2, Christopher Jenkins3, Philip G Campbell2.   

Abstract

A previously well 48-year-old man presented with presyncope and was found to be in complete heart block. Blood tests, echocardiography and coronary angiography were reported as normal, and a dual chamber permanent pacemaker was inserted. Six months later he re-presented with breathlessness. His chest X-ray showed cardiomegaly and echocardiography revealed a 4.4 cm pericardial effusion. A CT thorax revealed a mass originating from the intra-atrial septum, extending into the right atrium and ventricle. There were multiple pulmonary lesions suspected to be metastases. Histology demonstrated high-grade B-cell lymphoma. He was treated with eight cycles of R-CHOP chemotherapy and showed good radiological and clinical improvement. Post-treatment echocardiography found severe left ventricular dysfunction with an ejection fraction of <20%. Heart failure medical therapy was optimised and the pacemaker was upgraded to a resynchronisation device. A repeat scan 6 months post device upgrade showed an improvement in ejection fraction to 45%-50%. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cancer - see oncology; haematology (incl blood transfusion); heart failure; pacing and electrophysiology; pericardial disease

Year:  2021        PMID: 33431472     DOI: 10.1136/bcr-2020-239356

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  2 in total

1.  A case of complete atrioventricular block associated with primary cardiac lymphoma reversed without cardiac pacemaker implantation.

Authors:  Bowen Hu; Jian Zhao; Xin Liang; Changzhen Ren; Na Li; Chun Liang
Journal:  J Int Med Res       Date:  2022-04       Impact factor: 1.671

2.  Diagnosis of rapidly progressed primary cardiac lymphoma in liver transplant recipient: A case report.

Authors:  Jianghua Li; Qiyun Liu; Quanzhou Peng; Shaohong Dong
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.